{"anticipatedPostingDate":"2029-02","denomUnitsSelected":"Participants","description":"Determination of anti-obinutuzumab antibodies in serum samples were performed using a validated enzyme-linked Immunosorbent Assay (ELISA) method. Participants were considered to be ADA positive if they were ADA negative or have missing data at baseline but develop an ADA response following study drug exposure (treatment-induced ADA response), or if they were ADA positive at baseline and the titer of one or more post baseline samples was at least ≥ 4-fold greater than the titer of the baseline sample (treatment-enhanced ADA response).","reportingStatus":"NOT_POSTED","timeFrame":"Up to approximately 11 years","title":"Number of Participants With Anti-Drug Antibodies (ADAs) Positive Post-Treatment","type":"SECONDARY"}